News Headline Summary

Teva (TEVA) says superior patient outcomes compared with current studies support B-R combo as first line for lymphomas

- Reports significantly prolonged progression free survival.
- Reports significantly prolonged overall survival.
- Says B-R combo shows superior patient outcomes vs standard.

11 Dec 2012 - 12:33 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: